Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q2 FY25 results · Jul–Sep 2024
Tatva Chintan Pharma Chem reported revenue from operations of ₹83.49 crore (down 13.6% from Q2 FY24) and net loss of ₹0.66 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 83.49 | 96.67 | −13.6% | 105.46 | −20.8% |
| Other income | 0.38 | 0.76 | −50.1% | 1.17 | −67.9% |
| Total income | 83.87 | 97.42 | −13.9% | 106.64 | −21.4% |
| Profit before tax | (1.02) | 11.21 | Turned loss | 6.81 | Turned loss |
| Net profit for the period | (0.66) | 7.78 | Turned loss | 5.21 | Turned loss |
| EPS, basic (₹) | (0.29) | 3.43 | Turned loss | 2.23 | Turned loss |
| Net margin (%) | -0.8 | 8.0 | 4.9 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 80.96 | 92.57 | −12.5% | 93.81 | −13.7% |
| Other income | 0.81 | 0.76 | +6.6% | 1.42 | −43.2% |
| Total income | 81.77 | 93.33 | −12.4% | 95.23 | −14.1% |
| Profit before tax | (1.58) | 11.71 | Turned loss | 2.14 | Turned loss |
| Net profit for the period | (1.11) | 8.20 | Turned loss | 1.51 | Turned loss |
| EPS, basic (₹) | (0.47) | 3.63 | Turned loss | 0.64 | Turned loss |
| Net margin (%) | -1.4 | 8.9 | 1.6 |
Consolidated
- Filed with BSE
- 11 Nov 2024, 10:40 IST
- Board meeting
- 25 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Nov 2024, 10:40 IST
- Board meeting
- 25 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE